Journal of Parasitic Diseases: Diagnosis and Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Rapid Communication - Journal of Parasitic Diseases: Diagnosis and Therapy (2024) Volume 9, Issue 1

Advancements in Antihelminthic Drugs: A Rapid Overview

Eleftherios Mylonaki *

Division of Infectious Diseases, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA

*Corresponding Author:
José L. Medina-Franco
Division of Infectious Diseases
Alpert Medical School of Brown University
Mexico City, Mexico

Received: 26-Dec-2023, Manuscript No. AAPDDT-24-129282; Editor assigned: 29-Dec-2023, PreQC No. AAPDDT-24-129282 (PQ); Reviewed:12-Jan-2024, QC No. AAPDDT-24-129282; Revised:17-Jan-2024, Manuscript No: AAPDDT-24-129282 (R); Published: 23-Jan-2024, DOI:10.35841/aapddt-9.1.174

Citation Mylonakis E. Advancements in anthelminthic drugs: a rapid overview, J Parasit Dis Diagn Ther. 2024; 9(1):174


This rapid communication provides a concise update on recent advancements in anthelminthic drugs, showcasing their impact on global health and the ongoing efforts to address challenges such as drug resistance and accessibility. The article underscores the importance of continued research and innovation in the fight against helminthic infections.


Helminthic infections, caused by parasitic worms, remain a persistent global health challenge, affecting billions of people, particularly in resource-limited settings[1, 2]. Antihelminthic drugs play a pivotal role in controlling and preventing the morbidity associated with these infections.

Current drug classes:

Broad-spectrum anthelmintics, including benzimidazoles, praziquantel, and ivermectin, have been the mainstay of helminth control for decades. This section briefly outlines the mechanisms of action of these drugs and their applications in treating various helminthic infections.

Challenges and emerging issues:

Despite the successes of existing drugs, challenges such as drug resistance, limited treatment options, and the need for pediatric formulations persist. The article discusses the emergence of resistance in soil-transmitted helminths and the importance of addressing these challenges to ensure the sustained efficacy of antihelminthic treatments.

Next-generation therapies:

Recent research has identified potential next-generation antihelminthic drugs with novel mechanisms of action. From repurposing existing drugs to exploring natural products and synthetic compounds, this section explores the exciting prospects for expanding the therapeutic arsenal against helminthic infections [3].

Combination therapies:

Combination therapies, inspired by successful strategies in antimalarial treatment, are gaining attention in the field of helminth control [4, 5]. The article highlights ongoing research into the synergistic effects of combining existing drugs and the potential benefits in delaying the development of drug resistance[6].

Paediatric formulations and access

The unique challenges posed by helminthic infections in children necessitate age-appropriate formulations [7, 8]. This section discusses efforts to develop pediatric-friendly formulations and strategies to improve the accessibility of antihelminthic drugs in vulnerable populations.

Community engagement and preventive strategies

The article emphasizes the importance of community engagement in promoting preventive strategies, including mass drug administration [9], hygiene education, and sanitation improvements. These community-based interventions complement antihelminthic drug treatments and contribute to sustained control efforts.

Technological innovations

Advancements in diagnostic technologies, pharmacokinetics, and genomic studies are enhancing our understanding of helminth biology and guiding the development of targeted therapies. The article briefly touches upon how these innovations contribute to precision medicine approaches in helminthic infections [10].


Antihelminthic drugs remain pivotal in the control of helminthic infections, but ongoing challenges necessitate continuous research and innovation. This rapid communication highlights the current landscape of antihelminthic drug development, showcasing advancements, emerging issues, and the multifaceted strategies needed to address the complexities of helminth control in diverse global contexts. As we navigate this dynamic field, collaboration, innovation, and a commitment to global health equity will be essential in the pursuit of effective and sustainable antihelminthic interventions.


Badiaga S, Brouqui P. Human louse-transmitted infectious diseases. Clin Microbiol Infect. 2012;18(4):332-7.

Indexed atGoogle ScholarCross Ref

Leung AK, Fong JH, Pinto-Rojas A. Pediculosis capitis. J Pediatr Health Care. 2005;19(6):369-73.

Google Scholar

Virrueta Herrera S, Johnson KP, Sweet AD, Ylinen E, Kunnasranta M, et al . High levels of inbreeding with spatial and host-associated structure in lice of an endangered freshwater seal. Mol Ecol. 2022;31(18):4593-606.

Indexed atGoogle ScholarCross Ref

Feldmeier H. Pediculosis capitis: new insights into epidemiology, diagnosis and treatment. Eur J Clin Microbiol. 2012;31:2105-10.

Indexed atGoogle ScholarCross Ref

Burgess IF, Lee PN, Brown CM. Randomised, controlled, parallel group clinical trials to evaluate the efficacy of isopropyl myristate/cyclomethicone solution against head lice. Pharma J ;280. 2008.

Indexed atGoogle Scholar

Jg M. Liesenfeld O. Toxoplasmosis. The Lancet. 2004;363(9425):1965-76.

Indexed atGoogle ScholarCross Ref

Fayer R, Xiao L, editors. Cryptosporidium and cryptosporidiosis. CRC Pre; 2007.

Indexed atGoogle Scholar

Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int. J. Parasitol. 2000;30(12-13):1217-58.

Indexed atGoogle ScholarCross Ref

Checkley W, White AC, Jaganath D, Arrowood MJ, Chalmers RM, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2015;15(1):85-94.

Indexed atGoogle ScholarCross Ref

Lindsay DS, Dubey JP. Toxoplasma gondii: the changing paradigm of congenital toxoplasmosis. Parasitol. 2011;138(14):1829-31.

Indexed atGoogle ScholarCross Ref


Get the App